The arrival of the drug in the country is creating significant interest within the healthcare community. This novel dual compound – affecting both GLP-1 and GIP receptors – shows a potentially effective option for https://australianpeptidestore.co/retatrutide-value-bundle-starter-kit-research-peptide-australian-peptide-store/